Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.

Cell Rep · 2014 · PMC4410967 · PMID 24931606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Compared with no α-syn mAb treatment, we observed a highly significant reduction of α-syn pathology in C1 and C2 at 7 and 14 days following treatment with Syn211 and Syn303 ( Figures S3B–S3D ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.